Only a handful of major companies have yet to report their results for the last quarter, and AI leader Oracle (ORCL) is one of them. The Q3 earnings season has largely brought solid results. As of Dec. 5, 99% of S&P 500 companies have reported, according to FactSet data, and analysts estimate a 13.4% jump in earnings per share during the third quarter. If it holds, that figure would mark the fourth straight quarter of double-digit earnings growth and an acceleration from the 12% earnings growth rate repor ...

Valuation and Market Position - Altria Group, Inc. is trading at a forward 12-month price-to-earnings (P/E) ratio of 10.46, which is below the Tobacco industry's average of 13.89, the Consumer Staples sector's 16.02, and the S&P 500's 23.46, indicating an attractive valuation [1] - Compared to major peers, Altria remains discounted, with Philip Morris International Inc. at 18.12, Turning Point Brands, Inc. at 24.78, and British American Tobacco p.l.c. at 11.82 [1] Stock Performance - Over the past month, Altria's stock rose 1.1%, outperforming Turning Point Brands' 0.9% gain and Philip Morris' 3% decline, while British American Tobacco led with a 3.4% increase [6] - The Consumer Staples sector and the tobacco industry saw declines of 0.3% and 1.2%, respectively, while the S&P 500 gained 0.8%, highlighting Altria's strong positioning [7] Financial Fundamentals - In Q3 2025, Altria's adjusted earnings per share (EPS) increased by 3.6% to $1.45, with year-to-date EPS up 5.9%, driven by higher adjusted operating companies income (OCI) and a lower share count [11] - The smokeable products segment maintained impressive adjusted OCI margins of 64.4%, supported by effective pricing strategies [11] Product Strategy - Marlboro's premium-segment share expanded to 59.6%, reinforcing Altria's pricing power and brand strength, while the Basic brand gained share without detracting from Marlboro [12] - Altria's oral tobacco portfolio, particularly the on! brand, showed growth with a nearly 1% increase in volume and adjusted OCI margins expanding to 69.2% [13] Strategic Initiatives - Altria's collaboration with KT&G aims to enhance international modern oral expansion and explore operational efficiencies in traditional tobacco [14] - The company has consistently returned cash to shareholders, marking its 60th dividend increase in 56 years, which supports its stability and long-term growth [14] Volume Challenges - Altria faces significant volume pressures, with cigarette shipment volumes falling 8.2% in Q3 and 10.6% year-to-date, attributed to macroeconomic strains and competition from unregulated flavored disposable e-vapor products [15] Earnings Estimates - The Zacks Consensus Estimate for Altria's earnings has seen mixed revisions, with the 2025 EPS estimate increasing by 1 cent to $5.44, while the 2026 estimate decreased by 1 cent to $5.56 [18] - Altria is projected to deliver solid earnings growth of 6.3% in 2025 and 2.3% in 2026, despite modest adjustments [18]

Core Insights - Phibro Animal Health (PAHC) shares have increased by 59.6% this year, significantly outperforming the industry and the S&P 500 [1][2] Company Performance - The company holds a Zacks Rank 1 (Strong Buy) and is benefiting from the strong performance of its Animal Health portfolio, particularly in vaccines and emerging markets [2][4] - Phibro markets around 800 product lines across approximately 90 countries, focusing on food and companion animals, and is expanding its product offerings in the companion animal sector [3][4] Revenue Growth - The surge in share price is attributed to strong traction in the Animal Health business, with medicated feed additives (MFA) revenues growing by 81% in Q1 of fiscal 2026, bolstered by the integration of Zoetis' MFA business [4][9] - Vaccine sales increased by 25% year over year in Q1 of fiscal 2026, with management identifying vaccines as a key growth driver [5][9] Global Expansion - Phibro's sales in Europe, the Middle East, and Africa rose by 44.4%, while Asia Pacific sales surged by 101.1% in Q1 of fiscal 2026, reflecting the company's successful global expansion strategy [6][9] Financial Estimates - The Zacks Consensus Estimate predicts a 32.1% increase in earnings per share (EPS) for fiscal 2026, reaching $2.76, and a 6.2% increase for fiscal 2027, reaching $2.93 [11] - Revenues for fiscal 2026 are projected to grow by 13.1% to $1.47 billion, with fiscal 2027 revenues expected to reach $1.51 billion, indicating a 2.8% increase [11]

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying strong candidates can be challenging due to inherent volatility and risks [1] Group 1: Company Overview - Donaldson (DCI) is highlighted as a recommended growth stock, possessing a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 13%, with projected EPS growth of 9.8% this year, significantly outperforming the industry average of 5.6% [4] Group 2: Financial Metrics - Donaldson's asset utilization ratio (sales-to-total-assets ratio) is 1.25, indicating that the company generates $1.25 in sales for every dollar in assets, compared to the industry average of 0.74 [5] - The company's sales are expected to grow by 3.4% this year, while the industry average is stagnant at 0% [6] Group 3: Earnings Estimates - There is a positive trend in earnings estimate revisions for Donaldson, with the current-year earnings estimates increasing by 0.8% over the past month [7] - The company has earned a Growth Score of B and holds a Zacks Rank 2 due to these positive earnings estimate revisions, positioning it well for potential outperformance [9]

Core Insights - The company has provided guidance indicating a 4% growth in EBITDA from 2025 to 2026 and an 8% growth in earnings [2] - The company expects to end the next year with a debt to EBITDA ratio of 30.8x, which is at the lower end of the 3.5 to 4.5x range [2] - Expansion capital expenditures (CapEx) have been raised from approximately $2.5 billion per year to over $3 billion per year for the next few years, driven by project opportunities and timing of spending [2] - The company sees significant opportunities in the midstream space, anticipating strong growth in EBITDA and earnings along with numerous investment opportunities [2]

All right, Drew, we got to start with that Nvidia news. Does this change your view of the AI trade. Earlier this week, as I mentioned, we saw Edard Denny say, "Go underweight Mag 7 and a lot of people trying to rotate their portfolios." The idea of opening up China not only to Nvidia, but maybe other names.Does that change your perspective. >> Not really to be honest with you, because this this area, the Mag 7, the AI trade, it's all been about upward revisions. And look, a lot of these numbers came out of ...

2024 was peak MAG7 earnings growth, peak tech earnings growth. In fact, that earnings growth slowed a touch into 2025. But because we had so much uncertainty emerge with respect to tariffs, where were interest rates going, slow economic conditions, the rest of the index really didn't put up much earnings acceleration.That's expected to change in 2026. The analyst consensus is thinking, look, the Fed's going to reduce interest rates. We're going to get some tax refunds coming in 2026.Maybe we'll have a littl ...

Market Overview - U.S. stock markets have shown strong performance in 2025, with the Dow, S&P 500, and Nasdaq Composite increasing by 13.1%, 17.1%, and 22.3% year to date, respectively [1] - Strong third-quarter earnings, solid economic fundamentals, and an anticipated interest rate cut by the Fed are expected to sustain market momentum through December [1] Corporate Focus - Five major companies with market capitalizations over $50 billion have been identified for investor focus in December, all of which have delivered double-digit returns in the past month: Carvana Co. (CVNA), Walmart Inc. (WMT), Applied Materials Inc. (AMAT), Freeport-McMoRan Inc. (FCX), and Merck & Co. Inc. (MRK) [2][8] Carvana Co. (CVNA) - Carvana's operational focus, scalable model, and cost-cutting efforts are attracting investor interest, with the acquisition of ADESA's U.S. operations enhancing its logistics and reconditioning processes [5][6] - Currently holding only a 1.5% share of the U.S. automotive retail market, Carvana has significant expansion potential [6] - The company reported an adjusted EBITDA of $637 million for Q3, up $208 million year-over-year, with industry-leading margins of 11.3% [7] - For the full year, Carvana forecasts adjusted EBITDA between $2 billion and $2.2 billion, an increase from $1.38 billion last year [7] - Expected revenue and earnings growth rates for Carvana are 44.8% and over 100%, respectively, for the current year [9] Walmart Inc. (WMT) - Walmart's diversified business model and strong omnichannel strategy have increased traffic to both physical and digital platforms, leading to steady grocery market share gains [10] - Significant enhancements in delivery capabilities include the Express On-Demand Early Morning Delivery service and partnerships with Salesforce and DroneUp [11] - Expected revenue and earnings growth rates for Walmart are 4.4% and 4.8%, respectively, for the current year [12] Applied Materials Inc. (AMAT) - Applied Materials is benefiting from a rebound in the semiconductor industry, particularly in foundry and logic sectors, with strong performance in its services segment [13][14] - The company has a diversified portfolio that supports growth across various sectors, including IoT and automotive [14] - Expected revenue and earnings growth rates for Applied Materials are 2% and 1%, respectively, for the current year [15] Freeport-McMoRan Inc. (FCX) - Freeport-McMoRan is expanding reserves through exploration activities and executing smelter projects in Indonesia, positioning itself to benefit from the automotive electrification trend [16] - The company is focused on reducing debt and maintaining solid financial health [16] - Expected revenue and earnings growth rates for Freeport-McMoRan are -1.9% and 0.7%, respectively, for the current year [17] Merck & Co. Inc. (MRK) - Merck's sales are driven by its blockbuster drug Keytruda and new product launches, with ongoing label expansions expected to sustain growth [18] - The company is pursuing M&A opportunities to diversify its pipeline beyond Keytruda, with recent approvals for new products [19] - Expected revenue and earnings growth rates for Merck are 1% and 17.4%, respectively, for the current year [20]

Market Bubble & Potential Weakness - The market may experience pressure as wealth is sold to provide necessary funds, regardless of a bubble [1] - Dislocations are expected in private equity and venture capital due to firms needing to support existing positions that may no longer be feasible [3] - Weakness may emerge in SAS and other software companies if their functions are replaced by AI or other technologies [4] - Issues have already surfaced in the private credit space [4] Earnings Growth & Market Safety - Strong double-digit earnings growth could safeguard the market [4] - The peak impact of physical and monetary stimulus from the previous year is expected to continue through the end of next year, potentially driving double-digit earnings growth into 2026 and beyond [4] - Continued strong tailwinds behind topline and double-digit earnings growth could mitigate the impact of dislocations [5] - The firm has a bullish S&P price target of 7,500, indicating confidence in strong earnings [6] Consumer & Consumption Dynamics - The firm is bullish on consumption but mixed on the consumer [7] - The top 10% of earners account for 50% of consumption [8] - The bottom third of earners account for only 15% of consumption [9] Inflation & Political Issues - Inflation is anticipated to be more of a political issue than an economic one in 2026 [9][11] - The affordability crisis will be intertwined with inflation and will be a central issue as the midterms approach [11] - The affordability crisis affects a plurality of people, particularly the bottom half of earners, making it a key political concern [12]

Core Viewpoint - Morgan Stanley has raised its S&P 500 year-end target for 2026 to 7,800, driven by strong earnings growth and AI-enhanced efficiency gains [1][2] Group 1: Market Outlook - The market's positive shift began in April 2025, reversing previous negative growth assumptions due to supportive government policies [2] - The government's "Big Beautiful bill" is expected to enhance capital expenditure and provide tax benefits for consumers in the first half of 2026 [2] - The Federal Reserve's actions are also contributing to market momentum [2] Group 2: Sector Performance - The market is anticipated to broaden beyond a few major names, with potential in sectors like consumer discretionary, underperforming financials, transports, and consumer products [3] - These sectors have low earnings multiples, which may lead to earnings surprises and subsequent multiple expansion [3] Group 3: Stock Recommendations - A list of 11 stocks has been curated based on analyst ratings and hedge fund sentiment, focusing on those with over 25% upside potential [6][7] - The methodology includes analyzing top holdings from quality factor ETFs and ranking them by analyst upside potential [6] Group 4: Company Highlights - **NVIDIA Corporation (NASDAQ:NVDA)**: - Hedge fund holders: 234, Analyst upside potential: 25.06% [8] - Recent partnerships with Mistral AI and AWS enhance its AI capabilities and cloud infrastructure [10][11] - **The Home Depot, Inc. (NYSE:HD)**: - Hedge fund holders: 104, Analyst upside potential: 25.93% [12] - Mixed opinions from analysts following Q3 2026 results, with revenue growth of 2.82% year-over-year to $41.35 billion, but EPS of $3.74 fell short of consensus [13][14] - The company is positioned for market share gains despite recent performance challenges [14][15]